How many insider trades does FilingIQ track for ENVB?

FilingIQ tracks 52 Form 4 insider transactions for ENVB (Enveric Biosciences, Inc.), covering filings from Feb 15, 2021 onwards. 8 of those were filed in the last 90 days.

Are ENVB insiders net buyers or net sellers?

Across the full Form 4 history for ENVB, 1 transactions (2%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does ENVB insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is ENVB in?

Enveric Biosciences, Inc. (ENVB) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $2.59M.

ENVB insider trading

NasdaqCM Healthcare

Enveric Biosciences, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

Last 90 days

Buys / sells

2% / 0%

Market cap

$2.59M

About Enveric Biosciences, Inc.

Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. The company offers product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. It also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. The company was founded in 2020 and is headquartered in Cambridge, Massachusetts.

Company website: www.enveric.com

ENVB insider activity at a glance

FilingIQ has scored 52 insider transactions for ENVB since Feb 15, 2021. The most recent filing in our index is dated Jun 1, 2026.

Across the full history, 1 open-market purchases and 0 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on ENVB insider trades is 58.0/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live ENVB trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,234

UNITED THERAPEUTICS Corp

APLS 277

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

GH 187

Guardant Health, Inc.

BMY 182

BRISTOL MYERS SQUIBB CO

HOLX 142

HOLOGIC INC

ADPT 140

Adaptive Biotechnologies Corp

KNSA 139

Kiniksa Pharmaceuticals International, plc

Frequently asked

How many insider trades does FilingIQ track for ENVB?: FilingIQ tracks 52 Form 4 insider transactions for ENVB (Enveric Biosciences, Inc.), covering filings from Feb 15, 2021 onwards. 8 of those were filed in the last 90 days.
Are ENVB insiders net buyers or net sellers?: Across the full Form 4 history for ENVB, 1 transactions (2%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does ENVB insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is ENVB in?: Enveric Biosciences, Inc. (ENVB) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $2.59M.

Methodology & sources

Every ENVB insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.